Skip to main content
Terug
ADMA logo

ADMA Biologics, Inc.

Datakwaliteit: 100%
Oversold
ADMA
NASDAQ Healthcare Biotechnology
€ 9,63
▼ € 1,70 (-15,00%)
Marktkapitalisatie: 2,29B
Dagbereik
€ 8,62 € 11,45
52-Weeksbereik
€ 8,62 € 25,67
Volume
32.418.638
50D / 200D Gem.
€ 16,39 / € 17,09
Vorige Slotkoers
€ 11,33

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 15,6 0,2
P/B 4,8 3,0
ROE % 35,6 3,5
Net Margin % 28,8 3,8
Rev Growth 5Y % 58,5 9,7
D/E 0,2 0,2

Koersdoel Analisten

Hold
€ 16,00 +66.1%
Low: € 14,00 High: € 18,00
Forward K/W
10,08
Forward WPA
€ 0,96
WPA Groei (sch.)
+0,0%
Omzet Sch.
637,57M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 2,30
€ 2,29 – € 2,30
 1,26B 1
FY2029 € 2,01
€ 2,00 – € 2,01
 1,13B 1
FY2028 € 1,62
€ 1,52 – € 1,71
 944,85M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 € 0,19 € 0,20 +8,1%
2025-11-05 € 0,16 € 0,16 0,0%
2025-08-06 € 0,14 € 0,15 +7,1%
2025-05-07 € 0,16 € 0,14 -12,5%
2025-03-03 € 0,15 € 0,14 -6,7%
2024-11-07 € 0,13 € 0,15 +15,4%
2024-08-08 € 0,08 € 0,13 +62,5%
2024-05-09 € 0,06 € 0,08 +33,3%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 58,45% annually over 5 years — strong growth
Earnings declined -25,67% over the past year
ROE of 35,56% indicates high profitability
Net margin of 28,80% shows strong profitability
Debt/Equity of 0,17 — conservative balance sheet
Generating 27,82M in free cash flow

Groei

Revenue Growth (5Y)
58,45%
Revenue (1Y)19,63%
Earnings (1Y)-25,67%
FCF Growth (3Y)169,91%

Kwaliteit

Return on Equity
35,56%
ROIC25,77%
Net Margin28,80%
Op. Margin37,53%

Veiligheid

Debt / Equity
0,17
Current Ratio6,71
Interest Coverage26,93

Waardering

P/E Ratio
15,61
Forward P/E10,08
P/B Ratio4,80
EV/EBITDA11,94
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19,63% Revenue Growth (3Y) 40,56%
Earnings Growth (1Y) -25,67% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 58,45% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 510,17M Net Income (TTM) 146,93M
ROE 35,56% ROA 23,54%
Gross Margin 57,39% Operating Margin 37,53%
Net Margin 28,80% Free Cash Flow (TTM) 27,82M
ROIC 25,77% FCF Growth (3Y) 169,91%
Safety
Debt / Equity 0,17 Current Ratio 6,71
Interest Coverage 26,93
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 15,61 Forward P/E 10,08
P/B Ratio 4,80 P/S Ratio 4,50
PEG Ratio -1,09 Forward PEG N/A
EV/EBITDA 11,94 Fwd EV/EBITDA N/A
Forward P/S 3,60 Fwd Earnings Yield 9,92%
FCF Yield 1,21%
Market Cap 2,29B Enterprise Value 2,29B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 510,17M 426,45M 258,22M 154,08M 80,94M
Net Income 146,93M 197,67M -28,24M -65,90M -71,65M
EPS (Diluted) 0,60 0,81 -0,13 -0,43 -0,61
Gross Profit 292,77M 219,55M 88,94M 35,27M 1,17M
Operating Income 191,44M 138,98M 21,63M -39,37M -58,37M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 624,24M 488,68M 329,18M 348,46M 276,25M
Total Liabilities 146,92M 139,66M 193,98M 196,49M 135,08M
Shareholders' Equity 477,32M 349,02M 135,21M 151,97M 141,17M
Total Debt 79,89M 82,12M 141,42M 154,44M 102,92M
Cash & Equivalents 87,63M 103,15M 51,35M 86,52M 51,09M
Current Assets 466,51M 331,41M 257,01M 270,40M 208,73M
Current Liabilities 69,54M 55,54M 49,81M 39,27M 30,38M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Value Value Investing (Warren Buffett)
#64 of 203
42

Recente Activiteit

Ingestapt Value Investing (Warren Buffett)
Mar 26, 2026